Item 8.01. Other Events.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. 99.1 Press Release titled "Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis," datedJanuary 3, 2022 . 99.2 Press Release titled "Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720," datedJanuary 4, 2022 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
--------------------------------------------------------------------------------
© Edgar Online, source